Patty Davis

Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies

D. Brander, Joseph O. Moore, J. Gockerman, 2014, Leukemia & lymphoma.

Overcoming Drug Resistance in Mantle Cell Lymphoma Using a Combination of Dose-Dense and Intense Therapy

F. Ali-Osman, L. Prosnitz, D. Niedzwiecki, 2010, Cancer investigation.

"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.

R. Neuwirth, K. Sullivan, L. Sutton, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia

M. Datto, C. Rehder, C. Decastro, 2012, Leukemia & lymphoma.

A Prospective Study of Bortezomib in Combination with Melphalan and Prednisone for Patients with Previously Untreated Multiple Myeloma.

C. Decastro, D. Rizzieri, N. Chao, 2005 .

Pre-Clinical and Interim Results of a Phase II Trial of Perifosine In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

N. Jiang, J. Gockerman, D. Friedman, 2010 .